文献速递前列腺癌

PI-RADS v2 分类预测活检 Gleason 3+4 前列腺癌的肿瘤学结局

PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
PubMed 文献 · J Urol · 2019-01-01

本研究回顾性分析 326 例接受机器人根治性前列腺切除术、术前活检 Gleason 评分 6-7 的患者,主要分析活检 Gleason 3+4 者。发现 PI-RADS v2 5 分与不良病理特征独立相关(多因素 OR 11.4),且 5 分者 2 年生化复发无生存率低于 4 分者。

要点

  • 活检 Gleason 3+4 患者中 PI-RADS v2 5 分预测不良病理(OR 11.4)。
  • 靶向活检 Gleason 3+4 者 PI-RADS v2 5 分与不良病理相关(OR 14.7)。
  • PI-RADS v2 4 分与 5 分者 2 年生化复发无生存率分别为 92% 与 58%。

核心结论

  • PI-RADS v2 5 分病变在活检 Gleason 3+4 患者中预测不良病理特征和生化复发无生存。
  • 术前 3T 多参数 MRI 可能作为独立于活检 Gleason 评分或活检类型的治疗结局预后标志物。

研究设计与样本

  • 回顾性队列研究,纳入 326 例术前模板和/或 MRI-超声融合活检 Gleason 6-7 且接受机器人根治性前列腺切除术的连续男性。
  • 主要分析活检 Gleason 3+4 患者,采用单因素和多因素 logistic 回归评估不良病理特征。
  • 次要结局采用 Kaplan-Meier 法评估生化复发无生存,并对活检 Gleason 6-7 患者进行类似分析。

主要发现

  • 活检 Gleason 3+4 患者中 PI-RADS v2 评分 0-2、3、4、5 分别占 27%、15%、36%、23%。
  • 单因素分析中 PI-RADS v2 5 分 vs 0-2 分预测不良病理特征 OR 10.7(95%CI 3.7-31,p≤0.001)。
  • 多因素分析调整术前 MRI 靶向活检后,PI-RADS v2 5 分与不良病理相关 OR 11.4(95%CI 3.7-35,p≤0.0001)。
  • 靶向活检 Gleason 3+4 患者中 PI-RADS v2 5 分与不良病理相关 OR 14.7(95%CI 1.5-146.9,p=0.02)。
  • 活检 Gleason 3+4 患者中 PI-RADS v2 4 分和 5 分者 2 年生化复发无生存率分别为 92% 和 58%。

临床怎么用

  • 对活检 Gleason 3+4 患者,术前 PI-RADS v2 5 分提示不良病理和生化复发风险较高,可辅助治疗决策。
  • PI-RADS v2 评分可作为独立于活检 Gleason 评分或活检类型的预后参考指标。

局限性

  • 回顾性研究设计,样本来自单中心前瞻性维护数据库。
  • 主要分析限于活检 Gleason 3+4 患者,部分亚组样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Three Tesla multiparametric magnetic resonance imaging with PI-RADS™ (Prostate Imaging Reporting and Data System) version 2 scoring is a common tool in prostate cancer diagnosis which informs the likelihood of a cancerous lesion. We investigated whether PI-RADS version 2 also predicts adverse pathology features mainly in patients with biopsy Gleason score 3 + 4 disease. MATERIALS AND METHODS: We reviewed the records of 326 consecutive men with a preoperative template and/or magnetic resonance imaging-ultrasound fusion biopsy Gleason score of 6-7 from a prospectively maintained database of men who underwent robotic radical prostatectomy. The primary analysis was done in patients with biopsy Gleason score 3 + 4 to assess the primary outcome of adverse pathology features on univariate and multivariate logistic regression. The secondary outcome was biochemical recurrence-free survival using the Kaplan-Meier method. Similar analysis was done in patients with a biopsy Gleason score of 6-7. RESULTS: Of men with Gleason score 3 + 4 findings 27%, 15%, 36% and 23% showed a PI-RADS version 2 score of 0-2, 3, 4 and 5, respectively. On univariate analysis PI-RADS version 2 category 5 predicted adverse pathology features vs categories 0-2 (OR 10.7, 95% CI 3.7-31, p ≤0.001). On multivariate analysis the PI-RADS version 2 category 5 was associated with adverse pathology when adjusting for preoperative magnetic resonance imaging targeted biopsy (OR 11.4, 95% CI 3.7-35, p ≤0.0001). In men with a targeted biopsy Gleason score of 3 + 4 prostate cancer PI-RADS version 2 category 5 was associated with adverse pathology (OR 14.7, 95% CI 1.5-146.9, p = 0.02). Of men with biopsy Gleason score 3 + 4 disease 92% and 58% with a PI-RADS version 2 score of 4 and 5, respectively, had 2-year biochemical recurrence-free survival. CONCLUSIONS: A PI-RADS version 2 category 5 lesion in patients with a biopsy Gleason score 3 + 4 lesion predicted adverse pathology features and biochemical recurrence-free survival. These findings suggest that preoperative 3 Tesla multiparametric magnetic resonance imaging may serve as a prognostic marker of treatment outcomes independently of biopsy Gleason score or biopsy type.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Faiena I, Salmasi A, Mendhiratta N, et al. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. J Urol. 2019. PMID: 30142318. doi:10.1016/j.juro.2018.08.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。